Get the Stockscreener App
3.365
3.31%
-0.105
Kodiak Sciences Inc stock is currently priced at $3.365, with a 24-hour trading volume of 427.35K.
It has seen a -3.31% decreased in the last 24 hours and a -37.29% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.52 pivot point. If it approaches the $3.32 support level, significant changes may occur.
Kodiak Sciences Inc Stock (KOD) Financials Data
Kodiak Sciences Inc (KOD) Net Income 2024
KOD net income (TTM) was -$260.49 million for the quarter ending December 31, 2023, a +21.97% increase year-over-year.
Kodiak Sciences Inc (KOD) Cash Flow 2024
KOD recorded a free cash flow (TTM) of -$195.61 million for the quarter ending December 31, 2023, a +22.93% increase year-over-year.
Kodiak Sciences Inc (KOD) Earnings per Share 2024
KOD earnings per share (TTM) was -$4.96 for the quarter ending December 31, 2023, a +22.38% growth year-over-year.
Kodiak Sciences Inc Stock (KOD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EHRLICH JASON | See Remarks |
Jun 16 '23 |
Sale |
9.23 |
2,258 |
20,841 |
61,924 |
| BORGESON JOHN A. | See Remarks |
Jun 14 '23 |
Sale |
9.42 |
1,448 |
13,640 |
175,332 |
| EHRLICH JASON | See Remarks |
Jun 14 '23 |
Sale |
9.42 |
1,132 |
10,663 |
58,688 |
Kodiak Sciences Inc Stock (KOD) Latest News
Kodiak (KOD) Counts on Tarcocimab Program Despite Setbacks
Zacks Investment Research
Kodiak (KOD) Stock Falls on Q4 Earnings Miss, Pipeline in Focus
Zacks Investment Research
Take the Zacks Approach to Beat the Market: NVIDIA, Dell, Modine in Focus
Zacks Investment Research
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
US Stocks Flat; Initial Jobless Claims Fall To 210,000
Benzinga
Merck (MRK) Unit to Buy Elanco's Aqua Business for $1.3B
Zacks Investment Research
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy. Its preclinical stage product candidates include KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate to target inflammation and abnormal angiogenesis in the pathogenesis of retinal vascular diseases; KSI-201, a recombinant mammalian cell expressed dual inhibitor antibody biopolymer bioconjugate for the treatment of wet AMD; and KSI-401, a recombinant mammalian cell expressed antibody biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is headquartered in Palo Alto, California.
COMPANY PROFILE
NameKodiak Sciences Inc
SectorHealthcare (1194)
IndustryBiotechnology (685)
Webkodiak.com
Phone650-281-0850
Employee28
Twitter
@kodiaksciences
SEC filings
Latest SEC Filings
Next earning date2024-05-13
Address2631 Hanover Street, Palo Alto, CA, United States (94304)
1.63%
0.37%
Cap:
|
Volume (24h):